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Abstract 
Ischemic strokes evoke blood-brain barrier (BBB) disruption and edema formation through a 
series of mechanisms involving Rho-kinase activation. Using an animal model of human 
focal cerebral ischemia, this study assessed and confirmed the therapeutic potential of Rho-
kinase inhibition during the acute phase of stroke by displaying significantly improved 
functional outcome and reduced cerebral lesion and edema volumes in fasudil- versus 
vehicle-treated animals. Analyses of ipsilateral and contralateral brain samples obtained from 
mice treated with vehicle or fasudil at the onset of reperfusion plus 4h post-ischemia or 4h 
post-ischemia alone revealed these benefits to be independent of changes in the activity and 
expressions of oxidative stress- and tight junction-related parameters. However, closer 
scrutiny of the same parameters in brain microvascular endothelial cells subjected to oxygen-
glucose deprivation ±reperfusion revealed marked increases in prooxidant NADPH oxidase 
enzyme activity, superoxide anion release and in expressions of antioxidant enzyme catalase 
and tight junction protein claudin-5. Co-treatment of cells with Y-27632 prevented all of 
these changes and protected in vitro barrier integrity and function. These findings suggest that 
inhibition of Rho-kinase after an acute ischemic attack improve cerebral integrity and 
function through regulation of endothelial cell oxidative stress and reorganisation of 
intercellular junctions. 
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Introduction 
    Stroke is the third leading cause of mortality and the primary cause of morbidity in the 
Western World. Ischemic strokes constitute about 85% of all stroke cases and develop 
through an interference with blood supply to the brain. Pathologically, ischemic stroke is 
characterised by initial excitotoxicity and ensuing secondary complications such as 
inflammation, edema formation, oxidative damage and apoptosis (Moskowitz, 2010). Given 
the long lasting nature of the secondary mechanisms and their capacity to influence patients’ 
outcome, it is of paramount importance to discover agent(s) that can target most, if not all, of 
these pathologies. Although to date several compounds with neuroprotective properties have 
been identified in experimental settings, their translation to clinical practice has been 
unsuccessful due to associated toxic side effects and/or availability of a limited therapeutic 
window after an ischemic episode (Sutherland et al., 2012).  
    Brain edema constitutes the main cause of death within the first week after an ischemic 
stroke and at molecular level is characterised by dissolution of tight junctions (TJs) that are 
formed between adjacent endothelial cells via interactions of key transmembrane proteins 
including claudins and occludin and prevent the entry of blood constituents into the brain 
parenchyma (Gebel et al., 2002). Bearing these in mind, it is reasonable to suggest that any 
pathological stimuli affecting the formation of TJs will also affect the permeability of the 
barrier that exists between the blood and the brain, blood-brain barrier (BBB). 
    The molecular mechanisms involved in ischemia-evoked BBB damage remain largely 
unknown (Hacke et al., 1996). However, accumulating evidence have proven Rho-kinase as 
an important determinant of vascular tone and integrity due to its regulatory roles in cell 
proliferation, inflammation, stress fibre formation, myosin light chain phosphorylation and 
nitric oxide bioavailability (Sahai & Marshall, 2002; Van Aelst & D’Souza-Schorey, 1997; 
Allen et al., 2010; Takemoto et al., 2002). Indeed, increased expression and activity of Rho-
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kinase in endothelial cells have recently been shown to account for the hyperpermeability of 
an in vitro model of BBB subjected to oxygen-glucose deprivation (OGD) or hyperglycaemia 
(Allen et al., 2010, Srivastava et al., 2013). 
    Oxidative stress emerging from an imbalance between the production and metabolism of 
free radicals, in particular superoxide anion (O2
.-) during ischemic injury may also contribute 
to the BBB damage. NADPH oxidase accounts for much of the O2
.- generation in ischemic 
brain and cerebral cells and is composed of several cytosolic subunits and a membrane-bound 
cytochrome b558 that consists of gp91-phox and p22-phox subunits and is required for 
enzymatic activity and stability as a whole. Once produced, O2
.- is rapidly converted into 
H2O2 by superoxide dismutases which in turn is further metabolised to H2O by catalase and 
glutathione peroxidase (Shao & Bayraktutan, 2013; Bayraktutan U., 2005).  
    In light of the above, using an animal model of human focal cerebral ischemia, the current 
study aimed to assess the therapeutic effect of Rho-kinase inhibition on cerebral barrier 
integrity. It then comparatively examined the efficacies of rapid and slightly delayed Rho-
kinase inhibitions in barrier protection. Finally, it aimed to unravel the molecular mechanisms 
responsible for the putative beneficial effects by using ipsilateral versus contralateral brain 
slices as well as isolated brain microvascular endothelial cells (BMEC).  
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Materials and Methods 
    This study was conducted in accordance with the UK Animals Scientific Procedures Act, 
1986 (Project Licence 80/2015) and used adult male C57/BL6 mice (10-12 weeks at the time 
of surgery) supplied from Charles River (UK).   
In vivo cerebral ischemia 
    In order to induce focal cerebral ischemia, mice were subjected to middle cerebral artery 
occlusion (MCAO), as described previously (Gibson & Murphy, 2004). A total of 40 mice 
underwent transient MCAO; 2 mice died following MCAO and 1 mouse was sacrificed for 
welfare reasons. Anaesthesia was induced by inhalation of 4% isoflurane (in an NO2/CO2 
70/30% mixture) and maintained by inhalation of 1.5% isoflurane. Body temperature was 
maintained at 37±0.6°C using a heated mat and lubricant was applied to the eyes to prevent 
drying during surgery. Laser doppler flowmetry was used to measure blood flow of animals 
during MCAO and blood flow had to be reduced by at least 70% in order for animals to be 
included in analyses. After 45 min of MCAO the animal was re-anaesthetised and the 
filament was withdrawn in order to allow reperfusion. Mice received either fasudil (Sigma, 
10mg/kg dissolved in saline) or vehicle (i.e. saline only) via intraperitoneal injection.  Mice 
were randomly assigned to receiving fasudil at onset of reperfusion and again at 4h post-
MCAO, fasudil only at 4h post-MCAO or vehicle treatment. The experimenter was blinded 
to the treatment the mice had received prior to all subsequent analyses. 
Indicators of general well-being and functional outcome 
    Mice were weighed at 24 h post-surgery as an indicator of their general well-being. Body 
weights are presented as a percentage change compared with values recorded immediately 
prior to undergoing MCAO. Survival rates of animals per experimental group are presented 
as a percentage compared with the number of animals undergoing surgery. At 6 and 24 h 
post-MCAO each animal was assessed for focal deficits using a 28-point neurological scale 
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(Clark et al., 1998). In addition, at 24 h post-MCAO all mice underwent the grid test, as 
previously described (Gibson et al., 2011). Mice were assessed, during locomotion on a grid 
surface (grid openings of 2.5cm2), for the number of foot faults made by the ipsilateral and 
contralateral limbs. The foot faults are expressed as the number of errors made by the 
contralateral limbs as a percentage of the total errors made. 
Quantification of infarct volume and brain water content 
    In order to quantify the area of ischemic damage, mice (fasudil n=8, fasudil + 4h n=8, 
vehicle n=8) were assessed for lesion volume at 24 h post-MCAO as previously described 
(Gibson & Murphy, 2004). Infarct volume was calculated using an indirect method as 
described by Loihl et al. (1999) which avoids overestimation of infarct area due to edema. A 
group of mice undergoing MCAO (fasudil n=6, vehicle n=7) were sacrificed at 24 h post-
MCAO and analyzed for brain water content using the wet-dry method as previously 
described (Gibson et al., 2005). The percentage of water of each brain hemisphere was 
calculated as follows: percent brain water = wet weight-dry weight/wet weight x 100.  
Cell culture 
    BMEC (>5x105 cells) and astrocytes (>5x106 cells) isolated from cerebral cortex and 
cryopreserved at passage 1 were purchased from TCS CellWorks Ltd (Buckingham, UK). 
Cells between passages 3 and 6 were cultured in their respective specialized media to full 
confluence before exposure to clinically relevant periods of OGD alone (OGD-R, 4 h) or 
followed by reperfusion (OGD+R; 4/20 h) or a longer period of OGD alone (20 h). As 
exposures to longer periods of OGD+R (20/20 h) effectively restored in vitro barrier 
integrity possibly through nascent protein synthesis, the effect of this treatment regimen on 
the following parameters was not studied (Allen et al., 2010). To investigate the effects of 
Rho-kinase inhibition on a given parameter, in some experiments the cells were co-treated 
with a highly specific Rho-kinase inhibitor, Y-27632 (10 µM).  
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Establishment of an in vitro model of cerebral barrier 
    An in vitro model of BBB comprising BMEC and astrocytes was generated using transwell 
inserts (12 mm diameter, 0.4 µm pore size, Corning). For this, astrocytes were seeded onto 
the outer surface of inserts directed upside down. Following their overnight adherence to the 
membranes, the inserts were inverted the correct way and BMEC were seeded onto the inner 
parts. Both cell layers were cultured to confluence under normal conditions before exposing 
to the outlined experimental conditions.  
Measurements of in vitro barrier integrity and function 
    The integrity and function of BMEC and astrocyte co-cultures were assessed as previously 
described by measurements of transendothelial electrical resistance (TEER) and paracellular 
flux of Evan’s blue-labelled albumin (EBA; 67 kDa), respectively (Allen & Bayraktutan, 
2009; Allen et al., 2010).  
Immunoblotting 
    Equal quantities of total protein samples (10-30 g) obtained from ipsilateral and 
contralateral hemisphere slices or cultured BMEC were run on SDS-polyacrylamide gels (10-
15%) before transferring onto PVDF membranes. The membranes were then concurrently 
incubated with primary antibodies raised against β-actin (loading control, Sigma) and gp91-
phox, CuZn-SOD, catalase, occludin (Santa Cruz Biotech) or claudin-5 (Abcam). The 
primary antibodies were detected by appropriate species-specific infrared 700/800-tagged 
secondary antibodies prior to analyses of bands via Odyssey infrared imaging system (Li-Cor 
Biosciences). 
Measurements of total O2•– levels and NAD(P)H oxidase activity 
    The levels of total O2
•– were detected by cytochrome C reduction assay as previously 
described (Allen & Bayraktutan, 2009). Briefly, brain slices or cell pellets were sonicated in 
cold lysis buffer containing HEPES buffer (20 mM, pH 7.2), EGTA (1 mM), mannitol (210 
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mM) and sucrose (70 mM). Equal amounts of homogenate (100 µg) were then incubated with 
cytochrome C (50 µM) for 60 min at 37°C and absorbances were read at 550 nm.       
    NAD(P)H oxidase activity was measured with the lucigenin chemiluminescence assay. 
Briefly, samples of homogenates (100 µg) were incubated at 37°C in assay buffer (50 mM 
potassium phosphate buffer (pH 7.0), 1 mM EGTA, 150 mM sucrose, 5 µM lucigenin) 
containing the specific inhibitors for other free radical-generating enzymes i.e. nitric oxide 
synthase (NG-nitro-L-arginine methyl ester, 100 µM), mitochondrial complex I (rotenone, 50 
µM), xanthine oxidase (allopurinol, 100 µM) and cyclooxygenase (indomethacin, 50 µM). 
After 15 min NADH or NADPH (100 µM; Calbiochem) was added to initiate the reaction. 
The reaction was monitored every minute for 2 h and the rate of reaction calculated. Buffer 
blanks were also run for both assays and subtracted from the readings. 
Statistical analyses 
    All data are reported as mean±SEM and were analysed using either IBM SPSS 20.0 
software or GraphPad Prism version 5.0 for windows (GraphPad Software, San Diego, USA). 
Data were analysed by comparing the mean using student’s t-test or either one-way or two-
way analysis of variance followed by post hoc analyses, where appropriate. The criterion for 
statistical significance was P<0.05. 
 
Results 
Effect of Y-27632 on well-being and functional outcome following ischemic stroke 
    All experimental groups lost weight following MCAO. However, fasudil  treatment 
initiated at the onset of reperfusion (n=14) significantly reduced the amount of weight lost 
compared to vehicle treatment (n=15) whereas delayed fasudil treatment had no effect on 
body weight (n=8).  Mice were assessed for neurological function using a 6-point and 28-
point neurological score at 6 h and 24 h post-MCAO. Mice that had received fasudil 
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treatment, either at onset of reperfusion or 4h post-MCAO, performed significantly better on 
the 6-point neurological score compared to vehicle treatment (F2,32 = 7.809, P = 0.0008) and 
post-hoc analyses found that both fasudil-treated groups showed improved performance at 6h 
post-MCAO compared to vehicle treatment.  In addition, a significant difference was 
observed according to treatment (F=2,32 = 3.44, P = 0.037) when function was assessed using 
the 28-point neurological score although post-hoc analyses did not identify significant 
differences at any individual time points.Following MCAO, there was a significant effect of 
treatment on the number of foot faults (F2,32 = 10.28, P = 0.0004) and post-hoc analysis 
revealed that both fasudil treatment initiated at reperfusion, and fasudil treatment initiated at 
4h post-MCAO, resulted in significantly fewer foot faults compared with vehicle treatment (P 
< 0.01, Figure 1A-D).    
Effect of Y-27632 treatment on ischemic damage and brain water content 
    Calculation of lesion volume, from TTC staining, revealed via one-way ANOVA, a 
significant effect (P=0.016) of treatment on lesion volume (Figure 2A-B). Post-hoc analysis 
demonstrated a significant reduction (P<0.05) in lesion volume following either fasudil 
treatment initiated at the onset of reperfusion (16.57±2.31 mm3, n=8) or initiated at 4h post-
MCAO (17.11±19.93 mm3, n=8) compared to vehicle treatment (25.67±2.51 mm3, n=8).  In 
addition, analysis of the brain slices showed that treatment had a significant effect on the 
amount of swelling in the hemisphere ipsilateral to the stroke compared to the contralateral 
hemisphere (P = 0.014).  Post-hoc analysis revealed that the amount of swelling in the 
ipsilateral hemisphere was significantly reduced when fasudil treatment was initiated at 4h 
post-MCAO compared to animals receiving either fasudil initiated at reperfusion (P<0.05) or 
vehicle only (P<0.05).   The amount of edematous brain water content was measured by 
calculating the percentage brain water content. Following MCAO, there was a significant 
increase in the amount of ipsilateral edema as compared to contralateral oedema (F1,12 
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=11.86, P = 0.0023). However, the amount of ipsilateral edematous tissue was significantly 
reduced following Y-27632 treatment (n=6) compared to vehicle treatment (n=7, P<0.01).  
Effect of Y-27632 on cerebral protein expression and activities 
    To ascertain whether regulations of oxidative stress and TJ protein expressions may in part 
explain Rho-kinase inhibition-mediated improvements in barrier integrity, the levels of 
NADPH oxidase activity and O2
.- generation and prooxidant (gp91-phox), antioxidant (CuZn-
SOD, catalase) and TJ (occludin, claudin-5) protein expressions were examined in ipsilateral 
and contralateral brain samples obtained from MCAO mice treated with Y-27632 or vehicle. 
These revealed similar levels of expression and activity in all outlined parameters in both 
brain sections of a given animal and between those of Y-27632- versus vehicle-treated 
animals. Interestingly, no differences in Rho-kinase protein expression were observed in 
these experiments (Figure 3A-H).  
Effect of Y-27632 on oxidative stress-related elements in endothelial cells 
    As the use of brain slices containing a large number of neurons, astrocytes, glia and 
pericytes may explain the aforementioned similarities, the molecular causes of Y-27632-
mediated barrier protection were investigated using BMEC, the key cellular component of the 
BBB. Exposures of BMEC to OGD±R led to significant increases in NADPH oxidase 
activity and O2
.- release. Increases in oxidase activity were mirrored by those seen in gp91-
phox expression. Inhibition of Rho-kinase completely abolished all the aforementioned 
increases (Figure 4A-C). 
Effects of Y-27632 on endothelial cell antioxidant and TJ protein expressions  
     OGD±R did not have any impact on CuZn-SOD protein expression while significantly 
elevating that of catalase in HBMEC. Inhibition of Rho-kinase effectively neutralised 
catalase levels but failed to affect CuZn-SOD expression. Although OGD±R did not alter 
occludin protein expression, exposure to Y-27632 markedly enhanced its expression in all 
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experimental conditions. In contrast, exposure to OGD+R or longer periods of OGD 
increased claudin-5 protein levels which were completely neutralised by Y-27632 (Figure 
5A-D).  
Effects of Y-27632 on in vitro cerebral-barrier  
     OGD±R led to marked decreases in TEER and increases in EBA flux, signifying enhanced 
physical breakdown and paracellular permeability, respectively. Inhibition of Rho-kinase 
improved the in vitro barrier integrity and function solely after 4h OGD±R (Figure 6A-B).  
 
Discussion 
     In light of our recent investigation attributing the disruption of an in vitro model of human 
BBB to exaggerated Rho-kinase activation, the current study explored the therapeutic 
potential of post-ischemic Rho-kinase inhibition in protecting cerebral barrier using an 
animal model of human focal cerebral ischemia (Allen et al., 2010). Similar to the previous 
studies displaying neurovascular protection upon pre-ischemic inhibition of Rho-kinase by 
fasudil (Li et al., 2009; Rikitake et al., 2005), this study has revealed that early (at the onset 
of reperfusion plus 4h post-ischemia) and slightly delayed (4h post-ischemia alone) 
inhibitions of Rho-kinase after induction of cerebral ischemia also exerts neurovascular 
protection by demonstrating significantly improved neurological outcomes and reduced brain 
water and lesion volumes in fasudil- versus vehicle-treated mice that had been subjected to 
MCAO. Given that the overwhelming majority of patients receive neuroprotective therapy 
after, rather than before, an ischemic incidence takes place, this approach was therapeutically 
more valid. The increase in Rho-kinase expression is known to be closely asociated with 
infarct expansion and worsened neurological outcome and requires several hours to take 
effect (Rikitake et al., 2005, Yagita et al., 2007). This time-dependence may explain the equal 
effectiveness of early and delayed treatment regimens in subsiding cerebrovascular 
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complications. Of course, Rho-kinase-mediated suppression of other time-dependent 
pathologies such as inflammation and matrix metalloproteinase and inducible nitric oxide 
synthase activations that develop after an ischemic episode cannot be dismissed in this 
context (Liu et al., 2011; Li et al., 2009).  
    The extent of functional recovery after stroke differs enormously amongst patients and is 
dictated by the concordant concerted activities of a variety of processes like neurogenesis and 
angiogenesis. Rho-kinase inhibition has previously been implicated in neurogenesis under in 
vitro conditions and proven to be effective and safe in clinical settings even after an extended 
period of treatment. Indeed, a placebo-controlled clinical trial performed with patients who 
were able to receive the first injection of fasudil (60 mg, intravenous) within 48h of acute 
ischemic stroke onset and twice daily for 14 days thereafter exhibited radically improved 
neurological and clinical outcomes at 2 weeks after the initiation of treatment and at 1 month 
after the onset of symptoms, respectively (Shibuya et al., 2013; Ding et al., 2010). 
Intriguingly, a recent translational study has shown that inhibition of Rho-kinase by fasudil or 
Y-27632 can improve the functional recovery even after irreversible formation of brain 
lesions following photothrombotic stroke. Like the abovementioned trial, the animals here 
were also given an extended therapy, namely they received the first dose of Y-27632 or 
fasudil (both 30 mg) via oral gavage 3 days after the induction of stroke and then twice daily 
for 4 weeks (Lemmens et al., 2013). The present study unravels the remarkable therapeutic 
capacity of targeting Rho-kinase during acute phase of an ischemic stroke. Considering the 
eligibility of a selective subset of patients for thrombolysis and seminal role of Rho-kinase in 
evoking hemorrhagic transformation, these findings may be of considerable therapeutic 
importance (Ishiguro et al., 2012). 
    To investigate the mechanisms involved in Y-27632-dependent benefits, the putative 
changes in expression and activities of oxidative stress- and TJ-related parameters were 
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comparatively assessed in extracts of the ipsilateral and contralateral hemispheres obtained 
from Y-27632- or vehicle-treated mice. Aberrant TJ protein expressions and enhanced 
oxidative stress emerging from an imbalance between prooxidant and antioxidant enzyme 
expression and activities are implicated in the initiation and exacerbation of cerebral damage 
(Allen & Bayraktutan., 2009b). Analyses of NADPH oxidase activity, O2
.- generation and 
prooxidant (gp91-phox), antioxidant (CuZn-SOD and catalase) and tight junctional (occludin 
and claudin-5) elements at translational levels revealed similar results in both hemispheres of 
stroke-induced mice treated with Y-27632 or vehicle. Considering the regulatory role of Rho-
kinase in oxidative stress and TJ formation these results were somewhat surprising. However, 
given the microglial and endothelial localisation of Rho-kinase after an ischemic insult, they 
were expected (Ding et al., 2010b; Yagita et al., 2007). BMEC and microglia make up a 
small percentage of the overall cell population that is predominated by glia, astrocytes, 
neurons and pericytes, a fact supported by similar expression of Rho-kinase in the ipsilateral 
and contralateral hemispheres of both animal groups.  
    Since evaluation of Rho-kinase activity through staining for phosphorylated substrates of 
Rho-kinase, namely myosin light chain and adducin has shown ipsilateral blood vessels, in 
particular endothelia, as the main source of enzymatic activity in rats at 3-6 h after induction 
of ischemic injury by sodium laurate injection or MCAO (Yagita et al., 2007; Yano et al., 
2008), in vitro studies with BMEC were performed to further investigate the mechanisms that 
account for Y-27632-mediated barrier protection. In addition to the increases previously 
reported in Rho-kinase expression and activity, this study shows that exposure of BMEC to 
pathologically relevant periods of experimental ischemia significantly perturbs in vitro 
cerebral barrier integrity and function as evidenced by Y-27632-preventable decreases in 
TEER and increases in paracellular flux of EBA, respectively (Allen et al., 2010). This study 
also shows that alongside the normalisation of nitric oxide levels and restoration of actin 
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microfilaments concurred with disappearance of stress fibres, the suppression of oxidative 
stress and reorganisation of TJ proteins also contribute to the barrier-preserving effects of Y-
27632 (Allen et al., 2010). 
    TJ proteins occludin and claudin-5 seal the intercellular gaps between adjacent endothelial 
cells and thus form a selectively permeable barrier for the circulating molecules. Exposure of 
BMEC to OGD±R elevated the expression of claudin-5 protein, a hallmark of paracellular 
hyperpermeability in microvessels, without affecting that of occludin compared to the cells 
cultured in normoxia (Brooks et al., 2005, Willis et al., 2010). Inhibition of Rho-kinase 
activity during OGD±R kept claudin-5 protein expression at normal levels but increased that 
of occludin, a phenomenon has recently been coupled to the protective effects of Rho-kinase 
inhibitors on BBB and blood-tumor barrier after subarachnoid hemorrhage and treatment 
with endothelial-monocyte-activating polypeptide II, respectively (Fujii et al., 2012, Xie et 
al., 2012). It is noteworthy that the possible changes in phosphorylation pattern of occludin 
after OGD±R may also account for the beneficial effects of Rho-kinase inhibitors. Bearing in 
mind the correlation between enhanced phosphorylation of claudin-5 and the BBB 
dysfunction, this suggestion warrants further investigation (Yamamoto et al., 2008).   
    Enhanced endothelial cell oxidative stress characterised by selective increases in catalase 
expression, NADPH oxidase activity and O2
.- release may initiate or exacerbate the overall 
barrier dysfunction. As the inhibition of Rho-kinase activity effectively normalise these 
increases, it is safe to suggest that Rho-kinase acts upstream to a series of enzymes that 
determine the level of oxidative injury during or after an ischemic insult. In contrast, 
treatments of BMEC with Y-27632 failed to elevate the activity of CuZn-SOD that accounts 
for much of the metabolism of O2
.- to H2O2 in BMEC (Allen & Bayraktutan, 2009). Although 
these data imply that both anabolic and catabolic mechanisms contribute to excessive 
accumulation of O2
.- in BMEC, they do not rule out the possibility of cell-specific increases 
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in SOD activity by Rho-kinase inhibition in that immunohistochemical examination of rat 
brain slices subjected to OGD revealed  ≥50% of increases in SOD activity in cerebral cortex 
and hippocampus following treatments with fasudil (Li et al., 2009).  
    The critical role played by NADPH oxidase in modulating in vitro and in vivo cerebral 
barrier function under a variety of pathological phenomena including ischemia is well-
documented (Allen & Bayraktutan, 2009; Kahles et al., 2007, Genovese et al., 2011). Once 
generated, O2
.- appears to compromise barrier integrity in a direct fashion and through 
induction of BBB-related cell apoptosis orchestrated in part by the components of 
plasminogen-plasmin system and matrix metalloproteinases, notably urokinase plasminogen 
activator and MMP-2 (unpublished findings). Although the underlying mechanims remain to 
be elucidated, induction of proapoptotic protein Bax and the mitochondrial death pathway 
appear to account for Rho-kinase-evoked apoptosis in other cell lines such as cardiomyocytes 
and PC12 cells, a cell line derived from a pheochromocytoma of the rat adrenal medulla (Del 
Re et al., 2007; Li et al., 2011). 
    In conclusion, the current study demonstrates that inhibition of Rho-kinase activity, 
following the onset of cerebral stroke, may represent a viable therapeutic option to neutralise 
a variety of phenomena that contribute to developing pathology and the associated morbidity. 
    There are some limitations to this study. Measurements of the systemic Rho-kinase 
activity, oxidative stress and antioxidant capacity would have yielded additional information 
relating to the efficacies of early and delayed post-ischemic inhibition of Rho-kinase. The 
immunohistochemical analyses of ipsilateral and contralateral brain slices may have been 
useful in revealing if and to what extent the outlined parameters would be affected by OGD 
and treatments with Y-27632 in other cerebrovascular cells. 
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Figure legends 
Figure 1. erebral artery occlusion (MCAO). Mice were treated with fasudil initiated at onset 
of reperfusion (n = 14), fasudil initiated 4 h post-MCAO (n = 8) or vehicle treatment (n = 15). 
Body weights were measured as an indicator of general well-being and fasudil treatment, 
when initiated at reperfusion significantly reduced (*p < 0.05) the amount of weight lost 
compared to vehicle treatment (a). Fasudil treatment significantly improved functional 
outcome, as assessed using a 6-point and 28-point neurological score (b, c *p < 0.05, **p < 
0.05 versus vehicle treatment). Unilateral deficits, as measured by the number of contralateral 
foot faults expressed as the percentage of total errors made, were significantly higher in 
vehicle-treated animals than in fasudil-treated animals (d, **p < 0.01 versus vehicle 
treatment). Data are expressed as mean _ SEM. 
 
Figure 2. Representative images of slices stained with 2,3,5-triphenyltetrazolium chloride 
following either fasudil or vehicle treatment (a). Measurements of lesion volume revealed a 
significant reduction in lesion volume following fasudil treatment initiated either at the onset 
of reperfusion (*p < 0.05) or 4 h following the onset of middle cerebral artery occlusion 
(MCAO) (*p < 0.05) compared to vehicle treatment (b, n = 8/group). Fasudil treatment 
initiated at 4 h post-MCAO also significantly reduced the amount of swelling in the 
hemisphere ipsilateral to the stroke (c) compared to fasudil treatment at reperfusion onset (*p 
< 0.05) or vehicle treatment (*p < 0.05). Wet-dry analysis of brain water content revealed a 
significant effect of fasudil treatment 24 h following MCAO (d). Ischaemia resulted in a 
significant increase in ipsilateral water content compared to contralateral brain water content 
(p < 0.01). However, fasudil treatment (n = 6) significantly reduced the ipsilateral brain water 
content compared to vehicle treatment (n = 7, *p < 0.05). Data are expressed as mean _ SEM. 
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Figure 3. Comparative evaluation of (a) NADPH oxidase activity, (b) total O2˙ levels and (c) 
gp91-phox, (d) CuZn-SOD, (e) catalase, (f) occludin, (g) claudin-5 and (h) Rho-kinase 
protein expressions in homogenized contralateral (c) and ipsilateral (i) brain slices of mice 
subjected to middle cerebral artery occlusion prior to treatments with vehicle or fasudil. Data 
are expressed as mean _ SEM from six animals in each group.  
 
Figure 4. Assessment of NADPH oxidase activity (a), total O2˙  levels (b) and gp91-phox 
protein expression (c) in brain microvascular endothelial cells exposed to oxygen–glucose 
deprivation alone or followed by reperfusion (OGD _ R) in the absence or presence of Y-
27632 (10 lM). Data are expressed as mean _ SEM from four different experiments. *p < 
0.05 compared to the controls. 
 
Figure 5. Analyses of CuZn-SOD (a), catalase (b), occludin (c) and claudin-5 (d) protein 
expressions in brain microvascular endothelial cells subjected to oxygen–glucose deprivation 
alone or followed by reperfusion (OGD _ R) in the absence or presence of Y-27632 (10 lM). 
Data are expressed as mean _ SEM from four different experiments.*p < 0.05 compared to 
the controls. 
 
Figure 6. Measurements of cerebral barrier integrity (a) and function (b) by transendothelial 
electrical resistance (TEER, O cm2) and flux of Evans blue labelled albumin (EBA, lL) 
across an in vitro model of blood–brain barrier subjected to oxygen– glucose deprivation 
alone and followed by reperfusion (OGD _ R) in the absence and presence of Y-27632 (10 
lM). Data are expressed as mean _ SEM from four different experiments. *p < 0.05 compared 
to the controls, #p < 0.05 compared to short OGD _ R. 
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